• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

BD to shutter Minnesota Lutonix plant, layoffs ahead for 53

October 10, 2019 By Brad Perriello

Becton DickinsonBecton Dickinson (NYSE:BDX) is planning to close a Minnesota plant that makes its Lutonix drug-coated balloon next year, as the company looks to consolidate its peripheral intervention business.

The decision means layoffs for 53 of the New Hope, Minn., site’s 85 workers; the remaining 32 employees will either move to roles at BD’s Tempe, Ariz., location or work remotely, Franklin Lakes, N.J.-based BD said in a prepared statement. The closure is slated to into effect effective March 31, 2020.

“We are providing as much advance notice as possible to allow affected associates the opportunity to pursue other opportunities within BD or successfully transition to new employment,” the company said.

The move, spurred in part by the peripheral business consolidation, was reinforced by FDA action on paclitaxel-eluting devices like the Lutonix balloon and lower procedure volumes for drug-coated balloons, the company said.

Use of the devices plunged after a meta-analysis published in the Journal of the American Heart Assn. last December suggested that PAD patients treated with paclitaxel-coated balloons and stents could be at a higher risk for late death. An FDA panel convened to consider the evidence in June. In August the FDA said it wants more long-term safety and effectiveness studies on paclitaxel-eluting stents and balloons, and urged physicians to carefully consider when to use them.

“Drug-coated technology will continue to be an essential part of our product portfolio and company strategy moving forward. We take any decision that affects associates very seriously, and believe these actions are necessary to create a stronger business to support our customers and their patients,” BD said in the statement.

C.R. Bard announced its plans to acquire Lutonix for $325 million back in December 2011; Bard was later acquired by Becton Dickinson for $24 billion.

Filed Under: Cardiovascular, Drug-Device Combinations, Featured Tagged With: Becton Dickinson, Peripheral Artery Disease

IN CASE YOU MISSED IT

  • Abbott could pave new roads in diabetes management with dual sensor on the horizon
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS